Spyre Therapeutics, Inc.: Form 10-Q for the period ended Sep 30, 2025
Filed with the SEC on Nov 4, 2025 and accepted by EDGAR at Nov 4, 2025, 21:01 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2025-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Operating income | 3 months2025-07-01 to 2025-09-30 | −$56.9m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2025-01-01 to 2025-09-30 | −$152.4m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2025-07-01 to 2025-09-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2025-01-01 to 2025-09-30 | −$15.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2025-07-01 to 2025-09-30 | −$11.2m | us-gaap:NetIncomeLoss |
| Net income | 9 months2025-01-01 to 2025-09-30 | −$92.7m | us-gaap:NetIncomeLoss |
| Diluted EPS | 9 months2025-01-01 to 2025-09-30 | −$1.24 | us-gaap:EarningsPerShareDiluted |
| Operating cash flow | 9 months2025-01-01 to 2025-09-30 | −$124.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2025-09-30 | $64.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2025-09-30 | $504.6m | us-gaap:AssetsCurrent |
| Total assets | At period end2025-09-30 | $504.6m | us-gaap:Assets |
| Current liabilities | At period end2025-09-30 | $46.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2025-09-30 | $49.5m | us-gaap:Liabilities |
| Shareholders' equity | At period end2025-09-30 | $455.1m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001636282-25-000102. Last ingested by Listed: Oct 24, 2026, 15:14 ET. Listed shows no prices and gives no investment advice.